Physician profile
Robert D Cullom
NPI 1467439042
$746.75
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $65.50 · 2021: $18.73 · 2022: $147 · 2023: $253 · 2024: $20.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $178.88 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $135.24 | 2019 | |
| Rxsight INC | $127.04 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Alcon Vision LLC | $106.30 | 2019-2023 | Centurion |
| Oyster Point Pharma, INC. | $37.24 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.22 | 2019-2020 | |
| Allergan, INC. | $32.03 | 2019-2020 | |
| Sight Sciences, INC. | $27.17 | 2023 | Omni Surgical System |
| Harrow Eye, LLC | $20.39 | 2024 | Vevye |
| Bausch & Lomb Americas INC. | $19.28 | 2023 | Vyzulta |
| Shire North American Group INC | $16.30 | 2019 | |
| Oasis Medical, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cullom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.